This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Stocks to Monitor in a Dynamic Outpatient Home Health Industry
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, OPCH and ADUS are well-poised to gain.
Addus HomeCare (ADUS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ADUS vs. ASTH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. ASTH: Which Stock Is the Better Value Option?
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Addus HomeCare (ADUS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0.78% and 0.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
BDX Stock Declines Despite Launching BD IO Vascular Access System
by Zacks Equity Research
BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.
Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.
ECL Q3 Earnings Surpass Estimates, Revenues Miss, Margins Rise
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its third-quarter sales.
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results
by Zacks Equity Research
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
Here's Why You Should Add Veeva Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, escalating costs are concerning.
U.S. Physical Therapy (USPH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
U.S. Physical Therapy (USPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALGN Stock Rise on the Release of Invisalign Smile Architect Software
by Zacks Equity Research
Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.
Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products
by Zacks Equity Research
XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integer Holdings Q3 Earnings Surpass Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
by Zacks Equity Research
Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.
Talkspace Shares Decline Despite Partnership With Wisdo Health
by Zacks Equity Research
TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
by Zacks Equity Research
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
by Zacks Equity Research
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Reasons to Retain Ecolab Stock in Your Portfolio for Now
by Zacks Equity Research
ECL's focus on cost-efficiency programs raises optimism about the stock.